U.S. markets close in 29 minutes
  • S&P 500

    4,122.22
    -6.58 (-0.16%)
     
  • Dow 30

    33,709.52
    -91.08 (-0.27%)
     
  • Nasdaq

    13,830.49
    -69.70 (-0.50%)
     
  • Russell 2000

    2,230.19
    -13.28 (-0.59%)
     
  • Crude Oil

    59.62
    +0.30 (+0.51%)
     
  • Gold

    1,730.60
    -14.20 (-0.81%)
     
  • Silver

    24.83
    -0.50 (-1.97%)
     
  • EUR/USD

    1.1906
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6750
    +0.0090 (+0.54%)
     
  • GBP/USD

    1.3738
    +0.0033 (+0.24%)
     
  • USD/JPY

    109.4300
    -0.2200 (-0.20%)
     
  • BTC-USD

    60,223.29
    +266.93 (+0.45%)
     
  • CMC Crypto 200

    1,288.21
    -6.38 (-0.49%)
     
  • FTSE 100

    6,889.12
    -26.63 (-0.39%)
     
  • Nikkei 225

    29,538.73
    -229.33 (-0.77%)
     

Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26th, 2021 at 1:40 pm ET.

(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-svb-leerink-10th-annual-global-healthcare-conference-301231523.html

SOURCE Curis, Inc.